Delivery Order SPE2DB20D3103-SPE2DB26FL4E3
- Not listed
- The Defense Logistics Agency awarded a $4,852.12 delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. This competitively awarded, firm fixed-price contract is a non-set-aside delivery order with an ultimate completion date of November 4, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a child order under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a $36,425.77 delivery order to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40mg/4ml (2 units) under a firm fixed price contract. This delivery order, issued on October 27, 2025, with an ultimate completion date of November 24, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been selected to fulfill this medical supply...
- The Defense Logistics Agency awarded a $6,405.26 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 ml dosage. This is a non-set-aside, competitively awarded contract with a completion date of September 29, 2025, and performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader federal...
- The Defense Logistics Agency awarded a $3,715.82 delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL. This competitively awarded, firm fixed-price contract is set to conclude on October 28, 2025, with performance executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply relationship with the...
- The Defense Logistics Agency awarded a delivery order valued at $9,063.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of August 5, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single...
- The Defense Logistics Agency awarded a $13,075.97 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens, 40 mg/0.4 mL dosage. This contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency awarded a $4,843.93 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 8, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. The contract represents a single delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mL with a ceiling value of $1,132.95. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is set to be completed by October 24, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used...
- The Defense Logistics Agency awarded a $8,891.14 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) 40 mg/0.4 mL pre-filled pens on October 20, 2025, with an ultimate completion date of October 21, 2025. This non-competitive delivery order was issued under firm fixed price terms and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal medical supply needs...
- The Defense Logistics Agency awarded a delivery order valued at $16,858.64 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens containing 40 mg/0.4 mL of the immunosuppressant medication. This firm fixed price delivery order, issued on October 27, 2025, with an ultimate completion date of October 28, 2025, was competitively awarded without a set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB26FL4E3Delivery Order
The Defense Logistics Agency awarded a $17,091.36 delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a competitively awarded, firm fixed price contract with no set-aside designation and an ultimate completion date of October 29, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary pharmaceutical distribution operations supporting federal medical procurement. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of medications, vaccines, and medical supplies to military healthcare systems and other federal agencies. HUMIRA is a critical biologic immunosuppressant used in the treatment of autoimmune conditions including rheumatoid arthritis and inflammatory bowel disease, reflecting the breadth of specialty pharmaceutical products AmerisourceBergen delivers through its federal contract portfolio to support Defense Health Agency and other government healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.1k | 10/28/25 |